Cardiac surgeons at Herzzentrum Leipzig successfully performed the first implantation in Europe of the newly approved left ventricular assist device CorHeart 6 LVAD on November 4, 2026. The modern medical system had received its official CE mark approval shortly before the intervention following a successful clinical study phase. The recipient of the innovative system was 66-year-old Uwe Austel, who suffered from advanced heart failure. The operation proceeded smoothly, and the patient tolerated the procedure well, showing a clear improvement in his condition during the initial recovery phase.
The Challenge of Advanced Heart Failure and the Need for Mechanical Circulatory Support

Advanced heart failure is a progressive condition in which the cardiac muscle loses its capacity to pump a sufficient volume of blood to supply the body’s organs. As the disease advances, patients frequently experience debilitating shortness of breath, profound physical exhaustion, and severe limitations in daily activities. Conventional drug therapy and implantable cardioverter-defibrillators may eventually become insufficient to maintain circulatory stability, leading to acute life-threatening situations where mechanical circulatory support systems become essential to preserve life.
The medical history of 66-year-old Uwe Austel illustrates the clinical course of progressive cardiac failure. He had been living with diagnosed cardiac issues since 2008 and received an implantable cardioverter-defibrillator in 2022 to control dangerous arrhythmias. However, his physical condition deteriorated continuously from late 2025 onwards, culminating in an acute emergency in early October 2026 during which his defibrillator discharged repeatedly. Following initial stabilization in the intensive care unit in Zwickau, he was transferred to Herzzentrum Leipzig for specialized care.
Upon admission to the hospital, the patient was in a critical condition with acute dyspnea that prevented him from standing up or speaking. As noted by Dr. med. Joanna Jozwiak-Nozdrzykowska, Senior Physician at the Universitätsklinik für Kardiologie, detailed evaluation confirmed severe left ventricular failure, indicating that survival was not possible without a mechanical circulatory support system. The medical team initially stabilized the patient with medication and discussed the available treatment pathways with him and his family, leading to the shared decision to opt for the newly approved system.
First Implantation of the CorHeart 6 LVAD in Leipzig

The surgical intervention was conducted by Priv.-Doz. Dr. med. Alexey Dashkevich, Head of the Heart Transplantation and VAD Program at Herzzentrum Leipzig, together with Dr. med. Michal Nozdrzykowski, Senior Physician for mechanical circulatory support. The CorHeart 6 LVAD is a left ventricular assist device that was recently cleared for commercial use in Europe after completing its trial phase. The team at Herzzentrum Leipzig had already gained experience with the system prior to approval, having contributed two patient cases to the European clinical trial.
Reflecting on the milestone, Priv.-Doz. Dr. med. Alexey Dashkevich stated that being selected as the first European center to implant the CorHeart 6 LVAD after its commercial approval represents a significant achievement for the clinic. The surgical team expressed great satisfaction with the performance of the system and the clinical outcome of the procedure. The patient, Uwe Austel, reported feeling no pain after the surgery and noticed an immediate, meaningful enhancement in his daily quality of life while continuing his structured hospital recovery.
Herzzentrum Leipzig operates a certified Interdisziplinäre Abteilung für Herzinsuffizienz that provides a complete continuum of cardiac care. This includes tailored pharmacological therapy, catheter-based interventions, surgical procedures, mechanical assist devices, and heart transplantation. Demonstrating its commitment to cutting-edge research, the hospital had also implanted a biventricular system, the DuoCor BiVAS, in January 2026 under clinical and compassionate use criteria based on a specific patient’s needs prior to regular market approval.
Clinical Implications and Patient Options for Treatment in Germany

The newly introduced CorHeart 6 LVAD device offers distinct physical advantages for patients requiring long-term mechanical circulatory support. The pump unit is noticeably smaller and lighter than older models, while a narrower drive line cable allows greater flexibility and ease of movement during daily routine. Priv.-Doz. Dr. med. Alexey Dashkevich emphasized that having multiple distinct ventricular assist systems available is essential to match the individual physical and clinical characteristics of each patient suffering from heart failure.
For international patients traveling to Germany for specialized cardiovascular care, the commercial availability of the CorHeart 6 LVAD expands the spectrum of modern therapeutic options. German heart centers combine rigorous clinical evaluation with rapid access to newly approved medical technologies, ensuring high safety standards and individualized treatment strategies. Patients diagnosed with severe heart failure can seek comprehensive evaluation to determine whether mechanical circulatory support represents the appropriate next step in their care plan.
Early diagnostic assessment and collaborative planning remain critical components of managing complex cardiac cases. Healthcare providers and international families can contact the Interdisziplinäre Abteilung für Herzinsuffizienz at Herzzentrum Leipzig via dedicated telephone lines or email to arrange evaluations. By combining evidence-based medical regimens, minimally invasive procedures, and innovative assist devices, specialized cardiac teams ensure that every patient receives a personalized management strategy adapted to their health status and personal goals.
Source: Herzzentrum Leipzig GmbH